1stOncology™: Cancer Intelligence Service – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer

On May 1, 2026 Agendia, Inc., a leader in precision oncology for breast cancer, reported that it will present new data from the FLEX Study at the 27th Annual Meeting of the American Society of Breast Surgeons (ASBrS 2026), demonstrating that MammaPrint + BluePrint perform consistently across self-reported race in patients with genomically High-Risk, Basal-Type early-stage breast cancer who are receiving neoadjuvant chemotherapy. In multivariate analyses, pathological complete response (pCR) was driven by biological and treatment-related factors rather than race itself, supporting the robustness of genomic profiling across diverse patient populations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Poster #1062 | Friday, May 1, 6:00 p.m. – 7:00 p.m. PST | Presenter: Nathalie Johnson
Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy

In this real-world cohort of 451 patients with BluePrint Basal-Type early-stage breast cancer treated with neoadjuvant chemotherapy, 46 percent achieved a pCR. While pCR rates varied across self-reported race, multivariate analyses demonstrated that pCR was significantly associated with MammaPrint index, patient age and receipt of platinum-based chemotherapy, rather than race itself.

Whole transcriptome analysis revealed immune active transcriptional profiles among tumors achieving pCR across all racial groups. Importantly, among patients who achieved pCR, significant differences in pathway activation and immune cell composition were observed across race, highlighting biological heterogeneity within chemotherapy-sensitive Basal-Type disease. These findings demonstrate how BluePrint Basal-Type classification captures shared biology associated with response to therapy, while whole transcriptome analysis enables deeper characterization of race-associated molecular and immune differences among responders.

"The FLEX Study provides a unique opportunity to evaluate tumor biology in a population that is more broadly representative than what is typically seen in clinical trials," said Nathalie Johnson, Medical Director of the Legacy Cancer Institute and the Legacy Breast Health centers in Portland, Oregon, and first author of the study. "By including patients from diverse racial backgrounds, FLEX allows us to understand that patient outcomes are tied to shared and distinct biological features. More robust genomic and transcriptomic analyses are crucial in patient selection and in determining therapies that will result in higher pCR in all patient populations. This will help move us closer to equity in treatment outcomes."

"These results align with findings from our recent publication in npj Breast Cancer, which highlight the strength of MammaPrint + BluePrint as biology-driven tools that perform consistently across self-reported racial groups and underscore the importance of identifying patients with High Risk Basal-Type tumors, which are twice as common among Black women compared to White women," said William Audeh, MD, MS, Chief Medical Officer at Agendia. "By identifying tumors most likely to respond to therapy based on intrinsic biology, our assays support treatment decisions that are informed by molecular features rather than by demographic characteristics."

(Press release, Agendia, MAY 1, 2026, View Source [SID1234665014])

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

On May 1, 2026 Incyte (Nasdaq:INCY) reported that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy.

"The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD," said Bill Meury, Chief Executive Officer, Incyte. "Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-established role of Jakafi in clinical practice."

FDA approval was based on a clinical study which demonstrated that a single 55 mg Jakafi XR tablet taken once-daily (QD) is bioequivalent to a single 25 mg Jakafi tablet, the immediate-release (IR) dosage form, taken twice-daily (BID). This means that, based on key measures of steady-state drug exposure, it delivers the same active ingredient at comparable levels throughout the day, indicating the potential for similar clinical benefit.1

The safety of Jakafi XR has been established from adequate and well-controlled studies of Jakafi in adult patients with myelofibrosis, polycythemia vera, and adult and pediatric patients with acute and chronic graft-versus-host-disease. The most common adverse reactions associated with Jakafi in these studies include:

For certain patients with MF and PV: low platelet or red blood cell counts, bruising, dizziness, headache and diarrhea;
For patients with acute GVHD: low platelet counts, low red or white blood cell counts, infections and swelling;
And for patients with chronic GVHD: low red blood cell or platelet counts and infections, including viral infections.2
"Patients living with chronic conditions like MPNs and GVHD often struggle with managing complex treatment regimens or have multiple conditions," said Naveen Pemmaraju, M.D., Professor of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. "Since its initial approval in 2011, ruxolitinib has helped transform the treatment landscape for patients with MPNs and GVHD. With the approval of Jakafi XR, appropriate patients now have the choice of a single daily tablet." Researchers at UT MD Anderson have led several clinical trials in the development of ruxolitinib.

Incyte is committed to supporting patients and removing barriers to access medicines. Eligible patients in the U.S. who are prescribed Jakafi XR have access to IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering personalized patient support, including financial assistance and ongoing education and additional resources. More information about IncyteCARES is available by visiting www.incytecares.com or calling 1-855-452-5234, Monday through Friday, from 8 a.m. to 8 p.m. ET.

About Myelofibrosis
Myelofibrosis (MF) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs. MF occurs when a bone marrow defect results in an abnormal production of blood cells, causing scar tissue to form, which can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. MF can result from a progression of other bone marrow diseases, including polycythemia vera and essential thrombocythemia, or it can occur on its own.3

About Polycythemia Vera
Polycythemia Vera (PV) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs.3 PV occurs when bone marrow produces too many red blood cells, white blood cells and often platelets. Increased red blood cells and platelets can cause the blood to thicken, leading to an increased risk of blood clotting complications, including deep vein thrombosis, stroke or heart attack.4

About Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.5

About Jakafi XR (ruxolitinib) Extended-Release Tablets

Jakafi XR (ruxolitinib) extended-release tablets are a once-daily (QD) formulation of ruxolitinib, a first-in-class JAK1/JAK2 inhibitor, approved by the U.S. FDA for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; and chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

It is not known if Jakafi XR is safe or effective in children for treatment of myelofibrosis or polycythemia vera.

Jakafi XR and the Jakafi XR logo are trademarks of Incyte.

About Jakafi (ruxolitinib)

Jakafi (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the U.S. FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

It is not known if Jakafi is safe or effective in children for treatment of myelofibrosis or polycythemia vera.

Jakafi is marketed by Incyte in the U.S. and by Novartis as Jakavi (ruxolitinib) outside the U.S. Jakafi and the Jakafi logo are registered trademarks of Incyte. Jakavi is a registered trademark of Novartis AG in countries outside the United States.

IMPORTANT SAFETY INFORMATION

JAKAFI or JAKAFI XR can cause serious side effects, including:

Low blood counts: JAKAFI or JAKAFI XR may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking JAKAFI or JAKAFI XR and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start and regularly during your treatment. Your healthcare provider may change your dose or stop your treatment based on the results of your blood tests.

Tell your healthcare provider right away if you develop or have worsening symptoms such as:

unusual bleeding
bruising
tiredness
shortness of breath
a fever
Infection: You may be at risk for developing a serious infection during treatment with JAKAFI or JAKAFI XR. Tell your healthcare provider if you develop any of the following symptoms of infection:

chills
nausea
vomiting
aches
weakness
fever
painful skin rash or blisters
Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment.

Do not interrupt or stop treatment without talking to your healthcare provider. Tell your healthcare provider right away if you have any of the following after stopping treatment:

fever
trouble breathing
weakness
night sweats
feeling dizzy or lightheaded
pain in left upper stomach area or left shoulder
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will regularly check your skin during your treatment. Tell your healthcare provider if you develop any new or changing skin lesions during treatment.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking JAKAFI or JAKAFI XR and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis:
Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with JAKAFI or JAKAFI XR, including:

discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening.

Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with JAKAFI or JAKAFI XR, including:

swelling, pain, or tenderness in one or both legs
sudden, unexplained chest or upper back pain
shortness of breath or difficulty breathing
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of JAKAFI or JAKAFI XR include:

for certain types of polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea
for certain types of myelofibrosis (MF) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea
for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling
for chronic GVHD – low red blood cell or platelet counts and infections, including viral infections
These are not all the possible side effects. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking JAKAFI or JAKAFI XR, tell your healthcare provider about:

all the medications, vitamins, and herbal supplements you are taking
your medical conditions, including if you
have or had low white or red blood cell counts
have an infection
have or had tuberculosis (TB) or have been in close contact with someone who has TB
had shingles (herpes zoster)
have or had hepatitis B
have a high level of fat in your blood (high blood cholesterol or triglycerides)
have or have had a blood clot, heart attack, other heart problems, or stroke
are a current or past smoker
had cancer
have or had liver or kidney problems or are on dialysis. If you are on dialysis, JAKAFI or JAKAFI XR should be taken after your dialysis
have any other medical condition
Women should not take JAKAFI or JAKAFI XR while pregnant or planning to become pregnant. Do not breastfeed during treatment with JAKAFI or JAKAFI XR and for 2 weeks after the final dose.

How should I take JAKAFI or JAKAFI XR?

Take exactly as your healthcare provider tells you.
Do not change your dose or stop taking JAKAFI or JAKAFI XR without first talking to your healthcare provider. If you stop treatment, symptoms of your condition may return.
If you miss a dose, take your next dose at your regular time. Do NOT take 2 doses at the same time.
You may have regular blood tests during your treatment. Based on the results, your healthcare provider may change your dose or stop JAKAFI or JAKAFI XR.
IF YOU ARE PRESCRIBED JAKAFI:
Take JAKAFI 2 times a day or exactly as your healthcare provider tells you, with or without food.
JAKAFI may also be given through certain nasogastric tubes.
Tell your healthcare provider if you cannot take JAKAFI by mouth. Your healthcare provider will decide if you can take JAKAFI through a nasogastric tube. Ask your healthcare provider to give you specific instructions on how to properly take JAKAFI through a nasogastric tube.
IF YOU ARE PRESCRIBED JAKAFI XR:
Take JAKAFI XR 1 time a day with or without food.
Swallow JAKAFI XR whole. Do not split, crush, or chew.
Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with JAKAFI or JAKAFI XR at Jakafi.com.

(Press release, Incyte, MAY 1, 2026, View Source [SID1234665013])

Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer

On May 1, 2026 Sonire Therapeutics, a U.S.-based clinical-stage medical device company, reported the initiation of its first U.S. clinical trial, SUNRISE-II, evaluating its proprietary High-Intensity Focused Ultrasound (HIFU) therapy system for the treatment of pancreatic cancer.

The SUNRISE-II trial is designed to assess the safety and feasibility of Sonire’s ultrasound-guided HIFU system in patients with pancreatic cancer. The effort represents a key milestone in the company’s U.S. clinical and regulatory strategy, building on prior development experience in Japan, and marks an important step toward advancing treatment options for one of the leading causes of cancer-related deaths in the United States.

"Treatment options for pancreatic cancer remain extremely limited due to the complexity and location of the disease," said Tohru Satoh, President and CEO of Sonire Therapeutics. "Initiating SUNRISE-II in the United States is a defining milestone for our company. It enables us to begin building clinical evidence in a new market while advancing a treatment approach designed to be less invasive and more accessible for patients."

In March 2026, the first patient treated using the HIFU system was by Pejman Ghanouni, MD, PhD, at Stanford Medicine. Ghanouni is the principal investigator of the SUNRISE-II clinical trial.

According to the American Cancer Society, pancreatic cancer’s five-year survival rate remains approximately 13 percent, significantly lower than many other major cancers. Sonire’s HIFU therapy system leverages real-time ultrasound guidance to enable precise, minimally invasive tumor ablation. The platform allows physicians to monitor treatment in real time while delivering targeted energy to the tumor site, without the need for general anesthesia. This approach has the potential to reduce procedural burden on patients and providers while expanding access to treatment in outpatient settings.

The SUNRISE-II trial reflects Sonire’s broader strategy to expand into the U.S. clinical development program and generate high-quality evidence to support future regulatory submissions and global commercialization. By initiating clinical development at leading institutions, the company aims to accelerate the adoption of a new, less invasive treatment option for patients with difficult-to-treat tumors.

To learn more about SUNRISE-II, visit View Source;viewType=Card&rank=1

(Press release, SONIRE Therapeutics, MAY 1, 2026, View Source [SID1234665012])

Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026

On May 1, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, reported the presentation of new clinical data for DOC1021 (dubodencel), a first-in-class, patient-derived double-loaded dendritic cell investigational therapy, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, California, and at the American Academy of Neurology (AAN) Annual Meeting in Chicago, Illinois. The AACR (Free AACR Whitepaper) presentation features updated safety, survival, and immunologic data from the Company’s ongoing Phase 1 study in resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC), while the AAN presentation reports first results from the expanded access program (EAP) evaluating DOC1021 in combination with standard chemoradiation for adjuvant therapy of glioblastoma (GBM).

"Presenting clinical data at both AACR (Free AACR Whitepaper) and AAN underscores the breadth of the DOC1021 platform across multiple hard-to-treat cancers with significant unmet need," said Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology. "We are encouraged by the survival and immune response signals observed across both studies, including the expanded access results in glioblastoma, where all treated patients have surpassed 12-month overall survival. These findings reinforce our confidence in DOC1021 as we advance into randomized Phase 2 evaluation in GBM and continue to expand the platform’s clinical potential across additional indications."

"The AACR (Free AACR Whitepaper) data highlight the potential of DOC1021 to drive durable immune responses in pancreatic cancer, one of the most challenging malignancies we treat," said Dr. Benjamin Musher, MD, Professor of Medicine at Baylor College of Medicine and the study’s principal investigator. "In the post-operative setting, we are observing encouraging signals, including a favorable safety profile and evidence of immune activation, including upregulation of cytotoxic and memory T-cell markers. We have also seen prolonged survival in some patients. While these findings are preliminary, they suggest DOC1021 may engage the immune system in a disease historically resistant to immunotherapy, thus warranting further clinical investigation."

Pancreatic Cancer (AACR) (Free AACR Whitepaper) Highlights
The Phase 1 study (NCT04157127) evaluates DOC1021 in patients with resectable or borderline resectable PDAC who have undergone surgical resection. In Group A, DOC1021 was administered after surgery and completion of adjuvant chemotherapy; in Group B, DOC1021 was administered after surgery but prior to adjuvant chemotherapy.

As of March 2026, 5 of 7 patients remain alive, with 3 relapse-free; post-operative survival ranges from ~20 to 56 months, with ongoing follow-up.
DOC1021 was well tolerated, with primarily Grade 1–2 flu-like symptoms, including headache, fatigue, chills, and fever; no dose-limiting toxicities (DLTs) observed.
Increased granzyme B in CD8+ T cells and IFN-γ in CD4+ effector memory T cells, indicating enhanced cytotoxic functionality.
Increased CD127 expression was observed on circulating CD8+ and CD4+ T cells post-vaccination in most patients, consistent with upregulation of effector memory phenotypes.
Group B, evaluating DOC1021 administration post-surgery but prior to adjuvant therapy, is currently enrolling. A high-dose cohort (12 x 106 cells per administration) is planned, supported by the DLT evaluation from the current low-dose cohort and additional safety data from a completed Phase 1 trial (NCT04552886) and the ongoing Phase 2 trial (NCT06805305) in glioblastoma.
Glioblastoma (AAN) Highlights
The expanded access protocol evaluated DOC1021 in adult patients with new or recurrent GBM. Following surgical resection and standard chemoradiation, patients received 3 doses of DOC1021 (36 x 106 total cells) injected bilaterally near the deep cervical node chains every other week, administered concurrently with 6 weekly doses of interferon. Patients were treated from November 2024 through July 2025.

Seven patients (5 newly diagnosed, 2 recurrent) completed all three doses following surgery and chemoradiation; median age was 57.0 years; 5 of 7 patients were MGMT unmethylated.
All patients exceeded 12-month overall survival (OS), comparing favorably to the 88% 12-month OS observed in the Phase 1 study and to the ~60% historical benchmark with standard of care.
For the 2 recurrent GBM patients, post-operative survival from the time of second surgery is 18.5 and 22 months.
For the 5 newly diagnosed patients, post-operative survival from the time of initial surgery ranges from 12.1 to 15.2 months.
DOC1021 was safe and feasible to administer. The most common treatment-related adverse events were mild injection site reactions (Grade 1–2).
Increased CD127 expression on CD8+ (p < 0.05) and CD4+ (p < 0.001) T cells post-vaccination supports immune memory and persistence.
Randomized Phase 2 trial is enrolling to evaluate DOC1021 plus standard of care versus standard of care alone after surgical resection in newly diagnosed GBM patients.
Poster Presentation Details:

AACR Annual Meeting (San Diego, CA)
Title: Clinical and Immunologic Assessment of DOC1021 Dendritic Cell Therapy in Resectable or Borderline Resectable Pancreatic Cancer
Authors: Konduri, V., Trivedi, A., Liu, W., Namekar, M., Ernste, K., Wilson, G. G., Duus, E. M., Armaghany, T., Makawita, S. U., Camp, E. R., Van Buren, G., Aguilar, L. K., Musher, B. L., and Decker, W. K.

AAN Annual Meeting (Chicago, IL)
Title: DOC1021 Cell-based Immunotherapy in Combination with Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results from an Expanded Access Protocol of a Phase I Trial
Authors: Zhu, J‑J., Esquenazi‑Levy, Y., Hsu, S., Vu, M., Zvavanjanja, R. C., Trivedi, A., Liu, W., Namekar, M., Ernste, K., Tandon, N., Schumann, E. H., Duus, E. M., Aguilar, L. K., Georges, J. F., Konduri, V., and Decker, W. K.

About DOC1021
DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient’s dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.

The unique double-loading approach, a physiologic mimic of viral infection, unlocks a synergistic and exponentially more powerful tumor killing response that permits complete targeting of the total cancer antigen pool. Moreover, the approach does not require any molecular modification or genetic engineering of the patient’s immune cells and does not require preconditioning chemotherapy or high dose IL-2 for administration. DOC1021 is designed for outpatient administration and broad access via community cancer centers.

Diakonos currently has three actively enrolling clinical trials evaluating DOC1021, including a Phase 1 pancreatic cancer study (NCT04157127), a Phase 2 glioblastoma (GBM) study (NCT06805305) and a Phase 1/2 study in refractory melanoma (NCT07288112) supported by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 for the treatment of pancreatic cancer, GBM, and unresectable or metastatic cutaneous melanoma, reflecting the significant unmet medical need across these indications. Diakonos also received Orphan Drug Designation for the GBM program in January 2024.

(Press release, Diakonos Oncology, MAY 1, 2026, View Source [SID1234665011])

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

On May 1, 2026 Gilead Sciences, Inc. (Nasdaq: GILD) reported that its executives will be speaking at the following investor conferences:

BofA Securities Health Care Conference on Tuesday, May 12 at 2:20 PM Pacific Time
RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 11:00 AM Eastern Time
Bernstein Annual Strategic Decisions Conference on Thursday, May 28 at 11:00 AM Eastern Time
Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 9 at 1:20 PM Eastern Time

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

(Press release, Gilead Sciences, MAY 1, 2026, View Source [SID1234665010])